BeOne Medicines Ltd. (SHA:688235)

Market Cap	215.58B
Revenue (ttm)	30.30B
Net Income (ttm)	-2.85B
Shares Out	n/a
EPS (ttm)	-26.87
PE Ratio	n/a
Forward PE	98.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	839,810
Average Volume	2,992,986
Open	247.00
Previous Close	246.51
Day's Range	243.48 - 249.00
52-Week Range	111.22 - 268.47
Beta	0.30
RSI	52.39
Earnings Date	Aug 1, 2025

About BeOne Medicines

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688235

Financial Performance

In 2024, BeOne Medicines's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.

Financial numbers in USD